Navigation Links
Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
Date:5/15/2013

learned during the past decade of the Company's Generx clinical development program.
  • Publication of the paper, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors," authored by Gabor M. Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer, in the April issue of Molecular Therapy publication.  The publication outlines current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the optimization of clinical trial designs, including the Generx ASPIRE Phase 3 / registration study.
  • Expanded To Go Brands® VitaRocks® kids vitamin product line and broadened retail distribution of the newly-designed products into select nationwide Target stores.  Because of the unique manufacturing process of To Go Brands' VitaRocks platform, the Company now has the flexibility to expand the product line into formulas that could include enzymes, electrolytes, amino acids, vitamins and minerals, as well as nutrients, and into other applications including Over-the-Counter (OTC) drugs.
  • (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

    Financial ReportProduct sales for the three months ended March 31, 2013 totaled $599,000, compared to $20,000 for the same period in 2012. The increase in sales during the first quarter 2013 reflects sales from Cardium's To Go Brands health science-based operating unit (representing approximately 92% of total product sales) and sales of Cardium's Excellagen advanced wound care product (8% of total product sales). 

    Cardium's research and development costs for the first three months ended March 31, 2013 totaled $762,000, compared to $1.2 million for the three months ended March 31, 2012.
    '/>"/>

    SOURCE Cardium Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Cardium Announces Generx Publication In Molecular Therapy
    2. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
    3. Cardium Presents Year-End 2012 Financial Results And Recent Developments
    4. Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
    5. Cardium Receives ISO Certification for Excellagen
    6. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
    7. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
    8. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
    9. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
    10. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
    11. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... XRpro Sciences, Inc., a provider of ... services which features high throughput transporter and ion ... results for the year ended December 31, 2014. ... XRpro Sciences commented, "We have completed a number ... to commercial stage in large part by achieving ...
    (Date:3/27/2015)... -- Report Details  New study ... What does the future hold for top ... brand new report shows you potential revenues to 2025, ... Our 242-page report provides 185 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
    (Date:3/27/2015)... -- According to a new market research ... Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, ... - Global Forecasts to 2019 ", published by MarketsandMarkets, the ... Billion by 2019 with a CAGR of around 10.3% ... Browse   90   ma rket data ...
    Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
    ... 2011 US-based Life Technologies Corporation (Nasdaq: ... science solutions, announced today that it has launched a ... demand in the Asia Pacific regions of India, China, ... New Zealand. (Logo:   http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) ...
    ... GlaxoSmithKline (NYSE: GSK ) today announced that ... full approval for PROMACTA® (eltrombopag), an oral tablet that ... blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who ... splenectomy. PROMACTA initially received FDA orphan ...
    Cached Medicine Technology:Life Technologies Launches Asia Distribution Center in Singapore 2Life Technologies Launches Asia Distribution Center in Singapore 3Life Technologies Launches Asia Distribution Center in Singapore 4FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 2FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 3FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder 4
    (Date:3/29/2015)... March 29, 2015 “Health is an ... as we learn more about the cannabinoid system … ... March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ new ... endo-healing, is celebrated. Publius, of The Cannabis Papers: A ... Institutes of Health (PubMed) cannabinoid system (CS) articles discussing: ...
    (Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
    (Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
    (Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
    (Date:3/28/2015)... Chicago, IL (PRWEB) March 28, 2015 Centurion ... medical equipment auction on Thursday, April 2 at their Las ... Las Vegas, NV 89081. The sale, which consists of equipment ... will begin promptly at 9 a.m. PDT. , Buyers ... radiology and surgery equipment. “We are a one-stop-shop,” said Erik ...
    Breaking Medicine News(10 mins):Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
    ... Fla., Feb. 26 John Williams,a shrimp fisherman ... today before the House Subcommittee on Oversight and,Investigations ... safety. Williams criticized the Food and Drug Administration,s,(FDA) ... recommended Congress,take legislative actions., "On behalf of ...
    ... Customers and ... Private Insurance Corporations, OAKLAND, Calif., Feb. 26 ... organized by the California,Nurses Association/National Nurses Organizing Committee that ... a,9/11 rescue worker; Donna Smith, who has recently joined ...
    ... 690, Hospital Reach Settlement on Outstanding Disputes, ... General Hospital in Sandpoint, Idaho reached settlement on ... of Local 690,in Spokane, Washington., "This settlement ... to,perform their jobs capably despite management,s refusal to ...
    ... connects, educates and entertains sports world, KANSAS ... a new,online hotspot with Kansas City roots. A ... produce AthletixNation.com, the premier,community for all athletes, fans, ... AthletixNation.com is to have a positive impact,on the ...
    ... announces the release,of two new lifts, and a campaign ... open, twin mast design, and the SARA Lite, a ... twin masts, which improve stability and weight,distribution, but also ... functions, including Powered DPS (Dynamic Positioning System),are controlled via ...
    ... - Michel de Rosen to Continue as Chairman of the Board ... B. Soland Promoted to Chief Operating Officer -, ... announced today that, effective March 31, 2008, Vincent J.,Milano will succeed ... and has been elected to its board of directors. Mr.,de Rosen, ...
    Cached Medicine News:Health News:Testimony to Congress Denounces FDA Reliance on Self-Policing 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Nurses Convince Hospital to Return to Bargaining Table 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3
    ... (IGF-II) is a 7.5 kDa peptide which is ... to have mitogenic and metabolic actions involved in ... by binding to target cell receptors. IGF-II binds ... receptor, a monomeric protein which also serves as ...
    ... growth factor II (IGF-II) is a 7.5 kDa ... and is postulated to have mitogenic and metabolic ... IGF-II are mediated by binding to target cell ... Type II IGF receptor, a monomeric protein which ...
    ... growth factor II (IGF-II) is a 7.5 kDa ... and is postulated to have mitogenic and metabolic ... IGF-II are mediated by binding to target cell ... Type II IGF receptor, a monomeric protein which ...
    ... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
    Medicine Products: